Table 1. Important randomized trials comparing anthracycline and nonanthracycline adjuvant regimens in early breast cancer.
a
HER2 not assessed on all patients.
Abbreviations: AC, doxorubicin, cyclophosphamide; DC, docetaxel, capecitabine; DFS, disease‐free survival; EC, epirubicin, cyclophosphamide; IDFS, invasive disease‐free survival; neg, negative; OS, overall survival; pos, positive; RS,; TAC, docetaxel, doxorubicin, cyclophosphamide; TC, taxane, cyclophosphamide; TCH, docetaxel, carboplatin, trastuzumab; TCx6, .